Kintara Therapeutics, Inc. (KTRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KTRA Stock Price Chart Interactive Chart >
KTRA Price/Volume Stats
| Current price | $0.19 | 52-week high | $2.85 |
| Prev. close | $0.19 | 52-week low | $0.14 |
| Day low | $0.18 | Volume | 2,170,400 |
| Day high | $0.20 | Avg. volume | 1,855,430 |
| 50-day MA | $0.29 | Dividend yield | N/A |
| 200-day MA | $0.66 | Market Cap | 12.58M |
Kintara Therapeutics, Inc. (KTRA) Company Bio
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.
Latest KTRA News From Around the Web
Below are the latest news stories about Kintara Therapeutics Inc that investors may wish to consider to help them evaluate KTRA as an investment opportunity.
H.C. Wainwright Thinks Kintara Therapeutics’ Stock is Going to RecoverIn a report released today, Michael King from H.C. Wainwright maintained a Buy rating on Kintara Therapeutics (KTRA – Research Report), with a price target of $3.00. The company's shares closed last Monday at $0.45, close to its 52-week low of $0.33. According to TipRanks.com, King is a 4-star analyst with an average return of 11.9% and a 45.0% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kintara Therapeutics with a $2.83 average price target, representing a 548.8% upside. |
KTRA: A Farewell to GBMBy John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Second Quarter Fiscal Year 2022 Operational and Financial Results Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced second quarter fiscal year 2022 financial and operational results in a February 12 th press release and concurrently filed its 10-Q with the SEC. Highlights for the second quarter ended December 31, 2021 and |
Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate UpdateKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2021 and provided a corporate update. |
Maxim Group Remains a Buy on Kintara Therapeutics (KTRA)Maxim Group analyst Jason McCarthy maintained a Buy rating on Kintara Therapeutics (KTRA – Research Report) on February 2 and set a price target of $1.50. The company's shares closed last Friday at $0.45, close to its 52-week low of $0.33. According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Kintara Therapeutics is a Moderate Buy with an average price target of $3. |
Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and Chief Executive Officer, Robert E. Hoffman will present a corporate overview at the BIO CEO & Investor Conference, which is being held on February 14 – 17, 2022 at the New York Marriott Marquis in New York City, NY. |
KTRA Price Returns
| 1-mo | -37.07% |
| 3-mo | -48.65% |
| 6-mo | -73.61% |
| 1-year | -88.20% |
| 3-year | -88.48% |
| 5-year | -99.14% |
| YTD | -62.75% |
| 2021 | -60.16% |
| 2020 | 85.59% |
| 2019 | -79.71% |
| 2018 | -68.81% |
| 2017 | -65.83% |
Loading social stream, please wait...